Recombitek C7- 47M9.R0

Verify with FDA CVM →

10 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Recombitek C7- 47M9.R0

Administration Routes

Subcutaneous

Species Affected

Dog 10

Most Affected Breeds

Retriever - Labrador 2
Poodle - Miniature 2
Spitz - American Eskimo Dog 1
Spaniel - Cocker American 1
Bulldog - French 1
Pekingese 1
Deutsche Dogge, Great Dane 1
Poodle - Standard 1

Most Reported Reactions

Vomiting 4
Diarrhoea 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Shaking 2
Hyperglycaemia 2
Not eating 2
Injection site alopecia 2
Hyperpigmentation 2
Restlessness 1
Injection site pain 1
Anorexia 1
Adipsia 1

Outcome Breakdown

Outcome Unknown
6 (60.0%)
Recovered/Normal
3 (30.0%)
Ongoing
1 (10.0%)

Data Summary

Metric Value
Total adverse event reports 10
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Recombitek C7- 47M9.R0 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 10 adverse event reports referencing Recombitek C7- 47M9.R0, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Recombitek C7- 47M9.R0. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Recombitek C7- 47M9.R0 reports are Dog (10 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (2), Poodle - Miniature (2), Spitz - American Eskimo Dog (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Recombitek C7- 47M9.R0 are Vomiting (4), Diarrhoea (4), Lethargy (see also Central nervous system depression in 'Neurological') (3), Shaking (2). Of the 10 reports with a coded outcome, Outcome Unknown is the leading category at 60.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Recombitek C7- 47M9.R0.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial